Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 59

  • 1 133 clinical trials
  • 489 recruiting
  • 474 conditions
  • 28 countries

Conditions in this area

474 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic106Crohn's disease94Colorectal cancer90Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma40Adenocarcinoma pancreas36Pancreatic carcinoma metastatic35Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome31Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Colorectal adenocarcinoma16Endometrial cancer16+450

Clinical trials in Gastrointestinal disorders

1 133 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 133 clinical trials

Crohn's disease

Not recruiting

A study using the radiotracer vercirnon to examine its distribution in the body of healthy participants for research on Crohn's disease

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · Healthy volunteers
  • Substances:Vercirnon
  • Sponsor:AstraZeneca AB

Systemic scleroderma+3

Not recruiting

A Study of Cizutamig for Patients with Severe Autoimmune Inflammatory Diseases That Did Not Respond to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Hereditary haemorrhagic telangiectasia

Not recruiting

A Study of ALN-6400 Safety and Effectiveness in Adults with Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RNA, (UM-SP-(2′-DEOXY-2′-FLUORO)A-SP-GM-AM-AM-(2′-DEOXY-2′-FLUORO)A-CM-UM-CM-AM-UM-AM-GM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)A-UM-UM-GM-CM-AM-SP-CM-SP-AM), COMPLEX WITH RNA (UM-SP-GM-SP-CM-AM-AM-UM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)U-(2′-DEOXY-2′-FLUORO)A-UM-GM-AM-GM-UM-UM-UM-CM-UM-AM) 3′-[[(2S,4R)-1-[29-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-14,14-BIS[[3-[[3-[[5-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]PROPYL]AMINO]-3-OXOPROPOXY]METHYL]-1,12,19,25-TETRAOXO-16-OXA-13,20,24-TRIAZANONACOS-1-YL]-4-HYDROXY-2-PYRROLIDINYL]METHYL HYDROGEN PHOSPHATE] (1:1)
  • Sponsor:Alnylam Pharmaceuticals Inc.

Short-bowel syndrome

Not recruiting

A Study to Evaluate the Long-Term Safety of Glepaglutide in Adult Patients with Short Bowel Syndrome Who Participated in Previous Studies

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Adenocarcinoma pancreas

Not recruiting

A Study of Saruparib for Patients with Metastatic Pancreatic Cancer with Homologous Repair Deficiency as First Treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Saruparib
  • Sponsor:Centre Leon Berard

Gastrointestinal candidiasis

Not recruiting

Study of Rezafungin in Blood and Peritoneal Fluid for Patients with Suspected Intra-Abdominal Candidiasis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Rezafungin Acetate
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Colitis ulcerative

Not recruiting

Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Gastric cancer

Not recruiting

Study of FOLFIRI with domvanalimab and zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Gastric cancer+3

Not recruiting

Study of AZD4360 safety and effectiveness in adults with advanced solid tumors including gastric, gastroesophageal junction, biliary tract cancer and pancreatic cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:AZD4360
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil207 clinical trialsOxaliplatin197 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate69 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate53 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.